Matches in Nanopublications for { ?s ?p ?o <http://rdf.disgenet.org/resource/nanopub/NP432522.RAr6AX-bwd_o-95j3il799EUAYGBVBRcASdp9jN1REzbE130_provenance>. }
Showing items 1 to 9 of
9
with 100 items per page.
- source_evidence_literature type ECO_0000212 NP432522.RAr6AX-bwd_o-95j3il799EUAYGBVBRcASdp9jN1REzbE130_provenance.
- source_evidence_literature label "DisGeNET evidence - LITERATURE" NP432522.RAr6AX-bwd_o-95j3il799EUAYGBVBRcASdp9jN1REzbE130_provenance.
- source_evidence_literature comment "Gene-disease associations inferred from text-mining the literature." NP432522.RAr6AX-bwd_o-95j3il799EUAYGBVBRcASdp9jN1REzbE130_provenance.
- befree-2016 importedOn "2016-02-19" NP432522.RAr6AX-bwd_o-95j3il799EUAYGBVBRcASdp9jN1REzbE130_provenance.
- NP432522.RAr6AX-bwd_o-95j3il799EUAYGBVBRcASdp9jN1REzbE130_assertion wasGeneratedBy ECO_0000203 NP432522.RAr6AX-bwd_o-95j3il799EUAYGBVBRcASdp9jN1REzbE130_provenance.
- NP432522.RAr6AX-bwd_o-95j3il799EUAYGBVBRcASdp9jN1REzbE130_assertion wasDerivedFrom befree-2016 NP432522.RAr6AX-bwd_o-95j3il799EUAYGBVBRcASdp9jN1REzbE130_provenance.
- NP432522.RAr6AX-bwd_o-95j3il799EUAYGBVBRcASdp9jN1REzbE130_assertion SIO_000772 14976243 NP432522.RAr6AX-bwd_o-95j3il799EUAYGBVBRcASdp9jN1REzbE130_provenance.
- NP432522.RAr6AX-bwd_o-95j3il799EUAYGBVBRcASdp9jN1REzbE130_assertion evidence source_evidence_literature NP432522.RAr6AX-bwd_o-95j3il799EUAYGBVBRcASdp9jN1REzbE130_provenance.
- NP432522.RAr6AX-bwd_o-95j3il799EUAYGBVBRcASdp9jN1REzbE130_assertion description "[The ABL inhibitor Imatinib (Gleevec, STI571) has remarkable efficacy for treating chronic phase CML, and FLT3 inhibitors (e.g., PKC412) show similar promise in preclinical studies.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP432522.RAr6AX-bwd_o-95j3il799EUAYGBVBRcASdp9jN1REzbE130_provenance.